{"id":730,"date":"2022-01-21T10:43:37","date_gmt":"2022-01-21T10:43:37","guid":{"rendered":"https:\/\/beta.farmakologiportalen.no\/?post_type=fagstoff2&#038;p=730"},"modified":"2023-11-27T18:06:49","modified_gmt":"2023-11-27T18:06:49","slug":"nasjonale-kartleggings-og-harmoniseringsprosjekter-innen-klinisk-farmakologi","status":"publish","type":"fagstoff","link":"https:\/\/beta.farmakologiportalen.no\/fagstoff\/nasjonale-kartleggings-og-harmoniseringsprosjekter-innen-klinisk-farmakologi","title":{"rendered":"Nasjonale kartleggings- og harmoniseringsprosjekter innen klinisk farmakologi"},"content":{"rendered":"\n<p>Her er en oversikt over prosjektbeskrivelser og rapporter fra NFKFs ulike arbeidsgrupper<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><\/strong>Nasjonal harmonisering av begrepsbruk for farmakogenetisk fortolkning<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:<\/strong>&nbsp;Olav Spigset* og Rachel Aaker\u00f8y (St Olav), Silja Tuv og Kristin Nordal (OUS), Sigrid Narum&nbsp;og Espen Molden (SFP), Elena Prunes Jensen (Vestre Viken)<\/p>\n\n\n\n<p>*gruppens leder<\/p>\n\n\n\n<p><strong>Status:<\/strong>&nbsp;Gruppen oppnevnt av NFKF-styret mai 2020. Rapporter fra arbeidet er tilgjengelig i listen under.<\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1YdgAYZfsARru9VIDT8CHJrj3ZNSmpTeH&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Rusmiddeltesting &#8211; nasjonal rettleding<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe<\/strong>:&nbsp;Lena Aronsen&nbsp;(UNN) (LEDER), Linn \u00c5rnes (UNN), Arne Helland (St Olav), Jon Andsnes Berg (Haukeland), Cecilie H Thaulow (OUS), Knut Hjelmeland (OUS), Ilah Le Nygaard (OUS), Thor Hilberg (Furst), Jean-Paul Bernard (SFP), Elena Prunes Jensen (Vestre Viken)<\/p>\n\n\n\n<p><strong>Status<\/strong>:&nbsp;Rapport\/nasjonal rettleding ferdig november 2019,&nbsp;tilgjengeliggjort i farmakologiportalen.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1Nswl64V9JyFvBiXoBWwhKlDgzKzfTOKj&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Kartlegging: Legemiddelanalyser i Norge, 2000-2018<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe<\/strong>:&nbsp;<a href=\"mailto:andreas.westin@stolav.no\">Andreas Austgulen Westin<\/a>&nbsp;(St Olav) (LEDER),&nbsp;Guro Emilie Bratt&nbsp;(St. Olav), Jon Andsnes Berg (Haukeland),&nbsp;Berit Muan&nbsp;(OUS), Elisabeth Wiik (OUS),&nbsp;Sigrid Narum (Senter for psykofarmakologi), Linn \u00c5rnes&nbsp;(UNN), Elena Kvan&nbsp;(Vestre Viken),&nbsp;Thor Hilberg&nbsp;(F\u00fcrst), Olav Spigset (St Olav)<\/p>\n\n\n\n<p><strong>Status<\/strong>: Arbeid under planlegging.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1cbzTp4diI5pv4dDlduhGvhuDOvS7in89&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Referanseomr\u00e5der: Antiepileptika<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:&nbsp;<\/strong>Arne Reimers (St Olavs), Jon A Berg (Haukeland), Margrete Larsen Burns (OUS) og Cecilie Johannessen Landmark (OUS)&nbsp;<\/p>\n\n\n\n<p><strong>Status:<\/strong>&nbsp;Arbeidet er&nbsp;sluttf\u00f8rt, april 2017.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1sFAOdcnu16OPh9gnH_QnHZEdeXyGZSTM&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Referanseomr\u00e5der: Antikoagulantia<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:&nbsp;<\/strong>Halvor Lundgaard (St Olav), Roar Dyrkorn (St Olav), Espen Molden (Diakonhjemmet),&nbsp;Charlotte Stokes (Haukeland)<\/p>\n\n\n\n<p><strong>Status:<\/strong>&nbsp;Arbeidet er sluttf\u00f8rt, oktober 2016.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=19t936cq6Ml9-MPb1deOlnETvERcsmwwo&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Referanseomr\u00e5der: Benzodiazepiner, z-hypnotika og opioider<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:&nbsp;<\/strong>Arne Helland (St Olav) (LEDER),&nbsp;Lena Aronsen (UNN),&nbsp;Marianne Arnestad (Diakonhjemmet\/FHI),&nbsp;Sigrid Narum (Diakonhjemmet),&nbsp;Ingebj\u00f8rg Gustavsen (OUS),&nbsp;Kristin Nordal (OUS),&nbsp;Thor Hilberg (F\u00fcrst),&nbsp;Jon A Berg (Haukeland)<\/p>\n\n\n\n<p><strong>Status:&nbsp;<\/strong>Arbeid er sluttf\u00f8rt, februar 2016.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1JHEfsFmHV3aKkG-d5-Sld5WYARSt0w6n&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Referanseomr\u00e5der: Sentralstimulerende midler \/ ADHD-midler<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:&nbsp;<\/strong><a href=\"mailto:joachim.frost@stolav.no?subject=IS%3A%20Sentralstimulerende%20midler%20\/%20ADHD-midler%20%28kontakt%20via%20Farmakologiportalen%29\">Joachim Frost<\/a>&nbsp;(St Olav) (LEDER), Arne Helland (St Olav), Merete Vevelstad (OUS), Kari Kjeldstadli (OUS), Jean-Paul Bernard (SFP), Bettina Riedel (Haukeland), Erik Sveberg Dietrichs (UNN), Ragnhild Bergene Skr\u00e5stad (St Olav).<\/p>\n\n\n\n<p><strong>Status:<\/strong>&nbsp;Arbeidet er sluttf\u00f8rt, februar 2019.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1qnJR-SiSA4I7QcvHHXCKlgRoQi5fJvf4&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Varslingsgrenser for de vanligste klinisk farmakologiske analysene<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:<\/strong>&nbsp;<a href=\"mailto:trdn@helse-bergen.no?subject=Varslingsgrenser%20for%20klinisk%20farmakologiske%20analyser\">Trond Tr\u00e6tteberg Serkland<\/a>&nbsp;(Haukeland) (LEDER),&nbsp;Ilah Le Nygaard (OUS),&nbsp;Elena Kvan<a href=\"mailto:elekva@vestreviken.no\"><\/a><a href=\"mailto:elekva@vestreviken.no\"><\/a>&nbsp;(Drammen), Sigrid Narum (Diakonhjemmet), Joachim Frost (St Olav), Lena Aronsen (UNN), Tormod K Bj\u00e5nes (Haukeland)<\/p>\n\n\n\n<p><strong>Status:&nbsp;<\/strong>Arbeidet er sluttf\u00f8rt, oktober 2018.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=12ofz1cFxwHMfs1Ew3vzVosbP5x_unuCw&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Fortolkning: Harmoniserte vurderinger av cannabisinntak basert p\u00e5 U-THC-syre<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe<\/strong>:&nbsp;<a href=\"mailto:Hege-Merete.Krabseth@stolav.no?subject=IS%3A%20Harmoniseringsprosjekt%20cannabisinntak%20%28kontakt%20via%20Farmakologiportalen%29\">Hege-Merete Krabseth<\/a>&nbsp;(St Olav) (LEDER), Joachim Frost (St Olav), &#8230;. Trond T Serkland (Haukeland), (flere under oppnevning)<\/p>\n\n\n\n<p><strong>Status<\/strong>: Arbeid under planlegging<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1C7Bsn-p_Y136Olz9b9OetB721wgK2YIE&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Navnsettingsregler for nye psykoaktive stoffer (NPS)<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe\/&#8221;NPS-spr\u00e5kr\u00e5d&#8221;<\/strong>&nbsp;(geografisk N-&gt;S rekkef\u00f8lge): Ole-Martin Fuskev\u00e5g, Linn \u00c5rnes Pedersen (UNN), Per Ole Gundersen, Hege-Merete Krabseth,&nbsp;<a href=\"mailto:andreas.westin@stolav.no?subject=NPS%20spr%E5kr%E5d\">Andreas Austgulen Westin<\/a>&nbsp;(St Olav), Line Solum Amundsen,&nbsp;<a href=\"mailto:tormod.karlsen.bjanes@helse-bergen.no?subject=NPS%20spr%E5kr%E5d\">Tormod Bj\u00e5nes<\/a>&nbsp;(Haukeland), Merete Vevelstad, \u00c5se Marit Leere \u00d8iestad (OUS-Rettstoks)<\/p>\n\n\n\n<p><strong>Status:<\/strong>&nbsp;Arbeidet er sluttf\u00f8rt, februar 2019.&nbsp;Spr\u00e5kr\u00e5det kan konsulteres ved behov.<\/p>\n\n\n\n<p><strong>Dokumenter<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1TgwZzshr-OxcPwMAMzokSem1Vq4yQtuX&#038;usp=drive_web#list\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Referanseomr\u00e5der: Antidepressiva og antipsykotika<\/h2>\n\n\n\n<p><strong>Arbeidsgruppe:<\/strong>&nbsp;Opprinnelig gruppe: Hendset M, Sandvik P, et. al. Ny gruppe under etablering.<\/p>\n\n\n\n<p><strong>Status<\/strong>: Arbeid sluttf\u00f8rt i april 2008. Revisjon under planlegging.<\/p>\n\n\n\n<p><strong>Dokumen<\/strong><strong>ter:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/drive.google.com\/embeddedfolderview?id=1g3GYFAEOdYRfUcJG5-8sdiMY_nVHaMzA&#038;usp=drive_web#list\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Her er en oversikt over prosjektbeskrivelser og rapporter fra NFKFs  [&#8230;]<\/p>\n","protected":false},"author":2,"featured_media":0,"menu_order":0,"template":"","meta":{"footnotes":""},"categories":[23,24,26,28,29],"class_list":["post-730","fagstoff","type-fagstoff","status-publish","hentry","category-faglig-veiledning","category-farmakogenetikk","category-kvalitets-og-forskningsprosjekt","category-legemidler","category-rusmidler"],"_links":{"self":[{"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=\/wp\/v2\/fagstoff\/730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=\/wp\/v2\/fagstoff"}],"about":[{"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=\/wp\/v2\/types\/fagstoff"}],"author":[{"embeddable":true,"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=\/wp\/v2\/users\/2"}],"version-history":[{"count":2,"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=\/wp\/v2\/fagstoff\/730\/revisions"}],"predecessor-version":[{"id":1162,"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=\/wp\/v2\/fagstoff\/730\/revisions\/1162"}],"wp:attachment":[{"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beta.farmakologiportalen.no\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}